Ripertamab for children with frequent relapses or steroid-dependent nephrotic syndrome
Treatments studied
Part of Kidney & urinary clinical trials.
This trial tests a new medicine called Ripertamab to see if it can help children and young adults with nephrotic syndrome who keep relapsing or need steroids to stay in remission. It aims to offer a treatment option that may reduce relapses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older and have nephrotic syndrome that often comes back or needs steroids to control it.
- Before starting, your kidney disease must be in remission, meaning little or no protein in your urine.
- You haven't used certain immune-suppressing drugs in the last 2 months or other CD20 antibodies (like rituximab) in the last 6 months.
- Your kidneys are working well enough.
- You or your guardian agree to join and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ripeltumab in people with neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation of the optic nerve and spinal cord. It aims to reduce relapses by targeting the immune system.
This trial studies whether rituximab alone can help children with new-onset idiopathic nephrotic syndrome. It compares the treatment approach in order to see if it improves kidney recovery and reduces disease activity.
This trial tests rituximab, a medicine that affects the immune system, in children who have their first episode of steroid-sensitive nephrotic syndrome and are in remission at enrollment. It aims to see whether rituximab helps prevent relapse and improves kidney outcomes with fewer steroid needs.
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
This trial tests an experimental medicine called zuberitamab in children who have just had their first episode of nephrotic syndrome and responded well to steroid treatment. The medicine targets certain immune cells to help keep the disease from coming back.
This study tests an injection (SG301) that targets a protein called CD38 to help children whose nephrotic syndrome keeps coming back or depends on steroids. The goal is to see if the treatment can reduce relapses and the need for steroids.
Hear when a new FRNS/SDNS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.